JP6859275B2 - 膀胱がんの治療方法 - Google Patents

膀胱がんの治療方法 Download PDF

Info

Publication number
JP6859275B2
JP6859275B2 JP2017568016A JP2017568016A JP6859275B2 JP 6859275 B2 JP6859275 B2 JP 6859275B2 JP 2017568016 A JP2017568016 A JP 2017568016A JP 2017568016 A JP2017568016 A JP 2017568016A JP 6859275 B2 JP6859275 B2 JP 6859275B2
Authority
JP
Japan
Prior art keywords
mitomycin
liposome
prodrug
bladder cancer
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017568016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508589A5 (cg-RX-API-DMAC10.html
JP2018508589A (ja
Inventor
アルベルト・ガビゾン
パトリシア・オハナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patricia Ohana
Lipomedix Pharmaceuticals Ltd
Original Assignee
Patricia Ohana
Lipomedix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patricia Ohana, Lipomedix Pharmaceuticals Ltd filed Critical Patricia Ohana
Publication of JP2018508589A publication Critical patent/JP2018508589A/ja
Publication of JP2018508589A5 publication Critical patent/JP2018508589A5/ja
Application granted granted Critical
Publication of JP6859275B2 publication Critical patent/JP6859275B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017568016A 2015-03-17 2016-03-17 膀胱がんの治療方法 Expired - Fee Related JP6859275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134328P 2015-03-17 2015-03-17
US62/134,328 2015-03-17
PCT/US2016/022909 WO2016149516A1 (en) 2015-03-17 2016-03-17 Methods for the treatment of bladder cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020188037A Division JP2021035973A (ja) 2015-03-17 2020-11-11 膀胱がんの治療方法

Publications (3)

Publication Number Publication Date
JP2018508589A JP2018508589A (ja) 2018-03-29
JP2018508589A5 JP2018508589A5 (cg-RX-API-DMAC10.html) 2019-04-25
JP6859275B2 true JP6859275B2 (ja) 2021-04-14

Family

ID=56919480

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568016A Expired - Fee Related JP6859275B2 (ja) 2015-03-17 2016-03-17 膀胱がんの治療方法
JP2020188037A Withdrawn JP2021035973A (ja) 2015-03-17 2020-11-11 膀胱がんの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020188037A Withdrawn JP2021035973A (ja) 2015-03-17 2020-11-11 膀胱がんの治療方法

Country Status (5)

Country Link
US (1) US20180071253A1 (cg-RX-API-DMAC10.html)
EP (1) EP3270898B1 (cg-RX-API-DMAC10.html)
JP (2) JP6859275B2 (cg-RX-API-DMAC10.html)
AU (1) AU2016233143B2 (cg-RX-API-DMAC10.html)
WO (1) WO2016149516A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12171746B2 (en) 2019-01-11 2024-12-24 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
ATE252372T1 (de) 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
WO1998016201A1 (en) 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
HUP0201425A3 (en) 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
KR20040106547A (ko) * 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 비타민-마이토마이신 공액체
US10080807B2 (en) * 2014-06-09 2018-09-25 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin C

Also Published As

Publication number Publication date
EP3270898A1 (en) 2018-01-24
JP2021035973A (ja) 2021-03-04
CA2985330A1 (en) 2016-09-22
AU2016233143B2 (en) 2021-03-25
US20180071253A1 (en) 2018-03-15
WO2016149516A1 (en) 2016-09-22
AU2016233143A1 (en) 2017-10-19
JP2018508589A (ja) 2018-03-29
EP3270898A4 (en) 2018-10-31
EP3270898B1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
TWI866908B (zh) 用於治療肺部疾病的可吸入的緩釋組成物
KR102778887B1 (ko) 초음파역학 시술을 위한 미세거품-화학치료제 복합체
JP5570994B2 (ja) 治療薬を含有する新規な温度感受性リポソーム
JP4885715B2 (ja) イリノテカン製剤
Luo et al. Porphyrin-phospholipid liposomes with tunable leakiness
US20170273906A1 (en) Targeted liposomes encapsulating iron complexes and their uses
ES2333400T3 (es) Composiciones y procedimientos para tratar linfonas.
US20090092661A1 (en) Liposome compositions for in vivo administration of boronic acid compounds
KR20170132152A (ko) 나노입자를 이용한 종양 치료 조성물 및 방법
ES2258471T3 (es) Suministro de liposomas cationicos de taxanos a vasos sanguineos angiogenicos.
KR20150034517A (ko) 소수성 활성 성분 및 폴리펩티드의 복합체를 포함하는 리포좀, 및 그의 용도
JP2003522193A (ja) ホスホリパーゼａ２で分解可能な脂質誘導体を含有する脂質をベースとした薬物送達系、および治療におけるその使用
JP2021035973A (ja) 膀胱がんの治療方法
JP7096553B2 (ja) 上部尿路上皮癌の治療方法
US20040219204A1 (en) Method of treating angiogenic tissue growth
JP2024526800A (ja) Ｂｃｌ阻害剤のリポソーム製剤
CN107613962B (zh) 血清稳定组合物和用于光触发的材料释放的方法
CA2985330C (en) Methods for the treatment of bladder cancer
TWI607766B (zh) 核酸、醫用奈米粒子組以及醫藥組合物
CN114746124A (zh) 包含活性剂沉淀物的递送系统复合物和使用方法
JP2022517352A (ja) マイトマイシンｃのリポソーム化プロドラッグを含むリポソーム組成物および製造法
Bölükbaş Development of novel nanoparticle-based therapeutics for treatment of lung cancer
HK40097901A (en) Compositions and methods for delivery of anticancer agents with improved therapeutic index
HK40086650A (en) Liposome formulations for treatment of cancers and drug resistance of cancers
ZA200505740B (en) Method of treating angiogenic tissue growth

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201111

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201111

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20201124

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210127

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210325

R150 Certificate of patent or registration of utility model

Ref document number: 6859275

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees